Redcare Pharmacy stock holds support as analysts stick with bullish targets

Redcare Pharmacy N.V. (ISIN NL0012044747) stock is trading in the low-60-euro range as of August 18, 2026, with the shares testing a well-defined support area after a strong run earlier in the year.

Recent market data from European trading venues on August 18, 2026, show Redcare Pharmacy changing hands at about €60.33 on Lang & Schwarz, down 1.47 percent on the day and €0.90 below the previous close, while Xetra prints a €60.00 quote with nearly 10,000 shares traded in the referenced snapshot.

On Tradegate, the last full-session indication from August 17, 2026, shows Redcare Pharmacy at €64.30, representing a 5.93 percent gain over the prior five trading days but a 3.34 percent decline since the start of the year, illustrating the stock’s recent rebound within a broader, more volatile 2026 performance.

Analysts’ consensus still points well above the market price

Analyst and consensus data compiled for Redcare Pharmacy’s CBOE listing indicate a last traded level of €61.42 with a consensus target price near €64.42, implying upside of 4.88 percent from that reference point.

A separate analysis of active recommendations highlights that several research houses continue to rate the shares positively, with one recent overview mentioning six buy ratings and three hold ratings and an average price target of €74, positioning the stock well below the average target and close to the lowest current target of €40.

This gap between the current price in the low 60s and the average target in the mid-70s creates a visible valuation spread that investors will watch closely, especially with the shares hovering just above a technical support zone.

Technical picture centers on a strong support band

Technical commentary for Redcare Pharmacy describes a robust support band between €53.66 and €60.44, reinforced by a medium-term uptrend line and the 200-day moving average, making this zone a focal point for traders who monitor both trend and long-term support.

With the current price on August 18, 2026, clustered around €60, the shares are trading near the upper edge of that support corridor, leaving limited buffer before the lower boundary at €53.66 would be tested if selling pressure were to intensify.

Estimates revisions data for the CBOE listing show a price of €63.75, up 5.28 percent over the last five days but still down 4.27 percent since January 1, 2026, and 8.12 percent below an earlier reference level, underscoring that the stock has been recovering but not yet reclaiming its highs.

Recent trading and sector context

Market sector tools group Redcare Pharmacy under the broader health and retail category, with a Tradegate quote at €63.10 in one live snapshot on August 18, 2026, reflecting a 1.87 percent intraday decline, a 3.96 percent gain over five days, and a 2.50 percent drop since the beginning of the year.

Another Tradegate overview for August 17, 2026, records the €64.30 close and the same 5.93 percent five-day gain, aligning with the Lang & Schwarz and Xetra prints that show the shares consolidating in a narrow band after that move.

Data on shareholder structure indicate that institutional investors hold 25.84 percent of the company’s shares, with the company itself retaining 2.3 percent and free float at more than half of outstanding stock, supporting liquidity across German trading venues cited in the recent data.

Business model and digital pharmacy offering

Redcare Pharmacy operates as a European online pharmacy and healthcare platform, focusing on mail-order distribution of prescription and over-the-counter medications alongside health and wellness products.

The company’s digital-first model uses centralized logistics and fulfillment to serve customers in Germany and other European markets, leveraging regulatory frameworks that allow prescription handling and digital health integration.

By combining pharmacy services with an e-commerce experience, Redcare Pharmacy aims to capture growing demand for online medication ordering, repeat prescriptions, and bundled health products delivered directly to consumers.

Representative product: online medication delivery

One representative service in Redcare Pharmacy’s portfolio is its online prescription medication delivery offering, which lets patients submit prescriptions, receive verification, and have their medication shipped to their home through the company’s mail-order infrastructure.

This service underpins the company’s revenue base by driving recurring orders and cross-selling opportunities for additional health products in the same shipment, helping to smooth demand and support scale in logistics operations.

As regulators across Europe continue to support digital health initiatives, the online medication delivery service remains central to Redcare Pharmacy’s positioning in the competitive online pharmacy landscape.

Stock level and investor takeaway

For investors tracking Redcare Pharmacy stock, the key reference levels on August 18, 2026, are the cluster of prices around €60 on Xetra and Lang & Schwarz and the €64.30 Tradegate close from August 17, 2026, set against the technical support corridor between €53.66 and €60.44.

With consensus targets near €64.42 and broader analyst averages around €74, the shares trade at a discount to these views, but the durability of the support band and upcoming quarterly results will likely determine whether the low-60-euro range holds or gives way to a deeper consolidation.

Fact box

Company: Redcare Pharmacy N.V.

ISIN: NL0012044747

Ticker: RDC.DE

Exchange: Xetra

Price (as of August 18, 2026, 10:35 a.m. CET): €60.33

Sector / Industry: Health care, retail, mail-order pharmacy

Index membership: DAX sector benchmarks and regional indices